Overview

A Efficacy Study of PRX-00023 in Patients With Major Depressive Disorder

Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this randomized, double-blind, placebo-controlled study is to assess the safety and efficacy of PRX-00023 in patients with major depressive disorder.
Phase:
Phase 2
Details
Lead Sponsor:
Epix Pharmaceuticals, Inc.
Treatments:
Naluzotan